

UNITED STATES BANKRUPTCY COURT
SOUTHERN DISTRICT OF NEW YORK

In re: PURDUE PHARMA L.P., et al.,
Debtors

Case No.: 19-23649 (RDD)
Reporting Period October 1, 2020 to October 31, 2020

CORPORATE MONTHLY OPERATING REPORT

REQUIRED DOCUMENTS	Form No.	Document Attached	Explanation Attached
Schedule of Cash Receipts and Disbursements	MOR-1a	Yes	-
Bank Account Balances	MOR-1b	Yes	-
Consolidated Statement of Operations	MOR-2	Yes	-
Consolidated Balance Sheet	MOR-3	Yes	-
Schedule of Post-petition Taxes	MOR-4	-	Yes
Schedule of Payments to Insiders and Restructuring Professional Fees	MOR-5	Yes	-
Debtor Questionnaire	MOR-6	Yes	-

This Monthly Operating Report has been prepared solely for the purposes of complying with the monthly reporting requirements applicable in these chapter 11 cases and is in a format that the Debtors believe is acceptable to the United States Trustee. The financial information contained herein is limited in scope and covers a limited time period. Moreover, such information is preliminary and unaudited, and is not prepared in accordance with GAAP.

I declare under penalty of perjury that this report and the attached documents are true and correct to the best of my knowledge and belief.

J. R. house

Signature of Authorized Individual*

11/19/2020

Date

Jon house

Printed Name of Authorized Individual

11/19/2020

Date

*Authorized individual must be an officer, director or shareholder if debtor is a corporation.

In re: PURDUE PHARMA L.P., et al.,
Debtors

Case No.: 19-23649 (RDD)
Reporting Period October 1, 2020 to October 31, 2020

SCHEDULE OF CASH RECEIPTS AND DISBURSEMENTS (\$)

Case No.	Debtor Entity Name:	Net Receipts ²	Net Disbursements ¹
087-19-23648	PURDUE PHARMA INC.	\$ 17,500	\$ 448,417
087-19-23649	PURDUE PHARMA L.P.	111,525,561	116,155,780
087-19-23650	PURDUE TRANSDERMAL TECHNOLOGIES, L.P.	-	-
087-19-23651	PURDUE PHARMA MANUFACTURING L.P.	-	8,689
087-19-23652	PURDUE PHARMACEUTICALS L.P.	-	2,818,406
087-19-23653	IMBRIUM THERAPEUTICS L.P.	19,086	7,083,137
087-19-23654	ADLON THERAPEUTICS L.P.	-	3,144,156
087-19-23655	GREENFIELD BIO VENTURES L.P.	-	118,071
087-19-23656	SEVEN SEAS HILL CORP.	-	-
087-19-23657	OPHIR GREEN CORP.	-	-
087-19-23658	PURDUE PHARMA OF PUERTO RICO	-	942
087-19-23659	AVRIO HEALTH L.P.	-	6,294,129
087-19-23660	PURDUE PHARMACEUTICAL PRODUCTS L.P.	-	2,100
087-19-23661	PURDUE NEUROSCIENCE COMPANY	-	-
087-19-23662	NAYATT COVE LIFESCIENCE INC.	338,277	1,255,887
087-19-23663	BUTTON LAND L.P.	-	-
087-19-23664	PAUL LAND INC.	-	-
087-19-23665	QUIDNICK LAND L.P.	-	-
087-19-23666	RHODES ASSOCIATES L.P.	-	-
087-19-23667	RHODES PHARMACEUTICALS L.P.	17,872,603	14,495,916
087-19-23668	RHODES TECHNOLOGIES	2,164,516	4,199,353
087-19-23669	UDF LP	-	-
087-19-23670	SVC PHARMA LP	-	481,872
087-19-23671	SVC PHARMA INC.	-	-
Totals:		\$ 131,937,544	\$ 156,506,854

Footnotes

1) The Net Disbursements exclude intercompany transactions among Debtors

2) The Net Receipts exclude intercompany transactions among Debtors

In re: PURDUE PHARMA L.P., et al.,
Debtors

Case No.: 19-23649 (RDD)
October 31, 2020

BANK ACCOUNT BALANCES (\$)

Debtor	Bank	Account Number	Description	Balance as of Month End
Purdue Pharma L.P.	American Express National Bank (Restricted Cash)	xxxxxxx65041	CD	\$ 750,229
Purdue Pharma L.P.	Wells Fargo (Restricted Cash)	xxxx2400	Escrow	10,865,338
Purdue Pharma L.P.	Wells Fargo (Restricted Cash)	xxxx3900	Escrow	-
Purdue Pharma L.P.	East West Bank	xxxxxxx9773	LOC/Collateral	10,002,963
Purdue Pharma L.P.	East West Bank	xxxxxxx9808	LOC/Collateral	5,250,082
Purdue Pharma L.P.	East West Bank	xxxxxxx9836	LOC/Collateral	1,660,501
Purdue Pharma L.P.	East West Bank	xxxxxxx9136	Money Market Account	200,010,098
Purdue Pharma L.P.	Metropolitan Commercial Bank	xxxxxxx4813	Money Market Account	100,296,603
Purdue Pharma L.P.	Bank of Oklahoma	xxxxxx8720	Money Market Account	100,197,150
Purdue Pharma L.P.	JPMorgan/Dreyfus Funds #761	xxxx7720	Money Market Fund	-
Purdue Pharma L.P.	Goldman Sachs #520	xxxx8266	Money Market Fund	53,825,535
Purdue Pharma L.P.	Goldman Sachs #506	xxxx0462	Money Market Fund	551,584,620
Purdue Pharma L.P.	JP Morgan Chase	xxxxx5837	Operating	-
Purdue Pharma L.P.	East West Bank	xxxxxxx9129	Operating	17,334,855
Purdue Pharma L.P.	JP Morgan Chase	xxxxxxxxx8509	Operating	-
Purdue Pharma L.P.	JP Morgan Chase	xxxxx8921	Operating	-
Purdue Pharma L.P.	JP Morgan Chase	xxxxx2890	Operating	-
Purdue Pharma L.P.	East West Bank	xxxxxxx9388	ERISA	257,763
Purdue Pharma L.P.	Bank of Oklahoma	xxxxxx6017	Trust	15,149,214
Purdue Pharma L.P.	East West Bank	xxxxxxx9549	Operating	350,663
Purdue Pharma L.P.	East West Bank (Restricted Cash)	xxxxxxx9304	Restricted Account	-
Purdue Pharma L.P.	Wells Fargo (Restricted Cash)	xxxx1100	Trust	10,273,690
Purdue Pharma L.P.	Wells Fargo (Restricted Cash)	xxxx6600	Trust	59,182,455
Purdue Pharma L.P.	Metropolitan Commercial Bank (Restricted Cash)	xxxxxxxx6077	Trust	12,017,014
Purdue Pharma L.P.	Metropolitan Commercial Bank (Restricted Cash)	xxxxxxxx4767	Trust	93,025,008
Purdue Pharma L.P.	Wells Fargo (Restricted Cash)	xxxx0300	Trust	10,391,850
Purdue Pharma L.P.	Bank of Oklahoma	xxxxxx4018	Trust	25,105,936
Purdue Pharma Inc.	East West Bank	xxxxxxx9213	Operating	1,191,930
Purdue Pharma Inc.	JP Morgan Chase	xxxxx2866	Operating	-
Purdue Pharmaceuticals L.P.	Wells Fargo (Restricted Cash)	xxxx5300	Trust	125,969
Imbrrium Therapeutics L.P.	JP Morgan Chase	xxxxx1191	Operating	-
Imbrrium Therapeutics L.P.	East West Bank	xxxxxxx9241	Operating	-
Adlon Therapeutics L.P.	East West Bank	xxxxxxx9248	Operating	-
Adlon Therapeutics L.P.	JP Morgan Chase	xxxxx5999	Operating	-
Greenfield BioVentures L.P.	JP Morgan Chase	xxxxxx1118	Operating	-
Greenfield BioVentures L.P.	East West Bank	xxxxxxx9234	Operating	-
Purdue Pharma of Puerto Rico	East West Bank	xxxxxxx9185	Operating	-
Purdue Pharma of Puerto Rico	JP Morgan Chase	xxxxx5485	Operating	-
Avrio Health L.P.	East West Bank	xxxxxxx9199	Operating	-
Avrio Health L.P.	JP Morgan Chase	xxxxx9278	Operating	-
Purdue Neuroscience Company	East West Bank	xxxxxxx9227	Operating	-
Purdue Neuroscience Company	JP Morgan Chase	xxxxxx6535	Operating	-
Nayatt Cove Lifescience Inc.	JP Morgan Chase	xxxxxx8162	Operating	-
Nayatt Cove Lifescience Inc.	East West Bank	xxxxxxx9220	Operating	-
Button Land L.P.	East West Bank	xxxxxxx9297	Operating	-
Button Land L.P.	JP Morgan Chase	xxxxxx1875	Operating	-
Paul Land Inc.	East West Bank	xxxxxxx9290	Operating	-
Paul Land Inc.	JP Morgan Chase	xxxxx1859	Operating	-
Quidnick Land L.P.	JP Morgan Chase	xxxxx1891	Operating	-
Quidnick Land L.P.	East West Bank	xxxxxxx9304	Operating	-
Rhodes Pharmaceuticals L.P.	JPMorgan/Dreyfus Funds #761	xxxx3154	Money Market Fund	-
Rhodes Pharmaceuticals L.P.	East West Bank	xxxxxxx9269	Operating	-
Rhodes Pharmaceuticals L.P.	JP Morgan Chase	xxxxxx6220	Operating	-
Rhodes Technologies	JPMorgan/Dreyfus Funds #761	xxxx3153	Money Market Fund	-

In re: PURDUE PHARMA L.P., et al.,
Debtors

Case No.: 19-23649 (RDD)
October 31, 2020

BANK ACCOUNT BALANCES (\$)

Debtor	Bank	Account Number	Description	Balance as of Month End
Rhodes Technologies	JP Morgan Chase	xxxxxxxxx2509	Operating	-
Rhodes Technologies	JP Morgan Chase	xxxxxx6362	Operating	-
Rhodes Technologies	East West Bank	xxxxxx9262	Operating	-
SVC Pharma LP	JP Morgan Chase	xxxxx9855	Operating	-
SVC Pharma LP	East West Bank	xxxxxx9276	Operating	-
SVC Pharma Inc.	JP Morgan Chase	xxxxx9863	Operating	-
SVC Pharma Inc.	East West Bank	xxxxxx9283	Operating	-
Total				\$ 1,278,849,465

In re: PURDUE PHARMA L.P., et al.
Debtors

Case No.: 19-23649 (RDD)
Reporting Period October 1, 2020 to October 31, 2020

CONSOLIDATED STATEMENT OF OPERATIONS (\$M)^{1,2}

Consolidated Results of Purdue Pharma, L.P. and all Debtors except Purdue Pharma, Inc

	Current Month	2020 Year to Date	2019 Cumulative Filing to Date³
Net Sales	\$ 70	\$ 756	\$ 1,067
Cost of Goods Sold	(17)	(171)	(271)
Gross Profit	53	585	795
Sales and Promotion	(9)	(88)	(126)
Research and Development	(7)	(66)	(100)
General and Administrative	(7)	(76)	(116)
Legal Fees - Ordinary Course	(1)	(10)	(13)
Medical Affairs	(3)	(28)	(39)
Milestones & Alliances	(1)	(6)	(7)
Health Care Reform Fee	(1)	(9)	(13)
Other US	1	(1)	(2)
Incentive Bonus	(3)	(28)	(44)
Total Operating Expenses	(31)	(312)	(460)
Operating Profit	22	273	336
Legal Fees - Non-Recurring	(43)	(318)	(415)
Other ⁴	(1)	(73)	(80)
Total Non-Operating Expenses	(44)	(391)	(495)
Profit ⁵	\$ (22)	\$ (118)	\$ (159)

Footnotes

1) The numbers reflected in the Consolidated Statement of Operations are shown in MILLIONS.

2) The financial statements and supplemental information contained herein are limited in scope and cover a limited time period. Moreover, such information is preliminary and unaudited. The financial position and results of operations contained herein are not necessarily indicative of results which may be expected for any other period or for the full year and as a result, may not reflect the consolidated financial position and results of operations of the Debtors in the future.

3) Cumulative results for 2019 are beginning September 1, 2019 as operating results for the partial month from the filing date of September 15, 2019 to September 30, 2019 are not available.

4) Includes non-cash write downs of \$58M related to Rhodes Technologies assets.

5) The debtors historically updated contingencies as part of their year-end review with their auditors, Ernst and Young. Consistent with that practice, the Debtors have not assessed the need to adjust accruals for settlements as of October 31, 2020. The Debtors note, however, that they are in active settlement discussions with various creditors to settle outstanding claims and will incorporate any settlements as appropriate when the accruals are updated.

In re: PURDUE PHARMA L.P., et al.,
Debtors

Case No.: 19-23649 (RDD)
Reporting Period October 1, 2020 to October 31, 2020

PURDUE PHARMA, INC. STATEMENT OF OPERATIONS (\$000) ^{1,2}

	Current Month	2020 Year to Date	2019 Cumulative Filing to Date ³
Management Fee Income	\$ 30	\$ 292	\$ 407
General and Administrative Expenses	(1)	(30)	(59)
Operating Income	29	262	348
		-	
Income from Unconsolidated Associated Companies	(42)	(203)	(1,129)
Total Other Income	(42)	(203)	(1,129)
		-	
Pre-Tax Income	(13)	59	(781)
		-	
Income Tax Provision	3	(16)	196
		-	
Net Income	\$ (10)	\$ 43	\$ (585)

Footnotes

1) The numbers reflected in the Statement of Operations are shown in THOUSANDS.

2) The financial statements and supplemental information contained herein are limited in scope and cover a limited time period. Moreover, such information is preliminary and unaudited. The financial position and results of operations contained herein are not necessarily indicative of results which may be expected for any other period or for the full year and as a result, may not reflect the consolidated financial position and results of operations of the Debtors in the future.

3) Cumulative results for 2019 are beginning September 1, 2019 as operating results for the partial month from the filing date of September 15, 2019 to September 30, 2019 are not available.

In re: PURDUE PHARMA L.P., et al.,
Debtors

Case No.: 19-23649 (RDD)
October 31, 2020

CONSOLIDATED BALANCE SHEET (\$M) ^{1,2}		
Consolidated Results of Purdue Pharma, L.P. and all Debtors except Purdue Pharma, Inc.		Book Value
ASSETS		
CURRENT ASSETS		
Cash & Cash Equivalents	\$	1,023
Assets Held for Sale		1
Available For Sale Investments		1
Accounts Receivable, Net		120
Due From Associated Companies		7
Other Receivables		1
Inventories, Net		106
Prepaid Expenses & Other Current Assets		107
Restricted Cash		106
TOTAL CURRENT ASSETS		1,472
Property and Equipment, net		76
Investments at Cost		43
Investments in Associated Companies		-
Restricted Cash - Long-Term		148
Intangible Assets, Net		97
Other Assets		3
TOTAL ASSETS	\$	1,839
LIABILITIES AND EQUITY		
CURRENT LIABILITIES		
Accounts Payable	\$	39
Accrued Expenses		411
Due to Associated Companies		-
TOTAL CURRENT LIABILITIES		450
Other Liabilities		93
Due to Associated Companies		11
Liabilities Subject to Compromise ^{3,4}		3,018
TOTAL LIABILITIES		3,572
EQUITY		
Retained Earnings & Partners' Capital		(1,688)
Accumulated Other Comprehensive Loss		(45)
TOTAL EQUITY		(1,733)
TOTAL LIABILITIES AND EQUITY	\$	1,839

Footnotes

1) The numbers reflected in the Consolidated Balance Sheet are shown in MILLIONS.

2) The financial statements and supplemental information contained herein are limited in scope and cover a limited time period. Moreover, such information is preliminary, unaudited, and subject to change.

3) On September 15, 2019, the Company announced that it had reached an agreement in principle on a framework for settling the U.S. opioid litigation facing the Company with twenty-four (24) state attorneys general, analogous officials from five (5) U.S. territories, the Plaintiff's Executive Committee in the MDL, and co-lead counsel in the MDL. In connection with this agreement in principle, the shareholders of the Company are expected to contribute their ownership in the Company to a trust or other entity established for the benefit of claimants and the American people and a minimum of \$3.0 billion, with the potential for substantial further monetary contributions from the sales of their ex-U.S. pharmaceutical businesses. The Company has concluded that for accounting purposes a loss has been incurred and has recorded a provision in the amount of \$3.0 billion, in accordance with ASC 450, Accounting for Contingencies. This accounting provision of \$3.0 billion was recorded retroactively to December 31, 2018. The Company expects this amount to be paid by the shareholders of the Company. The Company will reclassify the liability associated with the cash settlement that is expected to be paid by the Company's shareholders to equity as a capital contribution if the settlement agreement is finalized and executed.

4) The debtors historically updated contingencies as part of their year-end review with their auditors, Ernst and Young. Consistent with that practice, the Debtors have not assessed the need to adjust accruals for settlements as of October 31, 2020. The Debtors note, however, that they are in active settlement discussions with various creditors to settle outstanding claims and will incorporate any settlements as appropriate when the accruals are updated.

In re: PURDUE PHARMA L.P., et al.,
Debtors

Case No.: 19-23649 (RDD)
October 31, 2020

PURDUE PHARMA, INC. BALANCE SHEET (\$000) ^{1,2}

	Book Value
Assets	
Currents assets:	
Cash and cash equivalents	\$ 1,192
Prepaid expenses	378
Due from Associated Companies	76
Other receivables	-
Total current assets	1,646
Investments	10,119
Deferred income taxes	147
Total assets	\$ 11,912
Liabilities and equity	
Current liabilities:	
Accounts payable	\$ 463
Due to Associated Companies	176
Accrued Expenses	178
Total liabilites	817
Common stock	1
Additional paid-in capital	499
Retained earnings	10,660
Accumulated other comprehensive loss	(65)
Total equity	11,095
Total liabilites and equity	\$ 11,912

Footnotes

1) The numbers reflected in the Consolidated Balance Sheet are shown in THOUSANDS.

2) The financial statements and supplemental information contained herein are limited in scope and cover a limited time period. Moreover, such information is preliminary, unaudited, and subject to change.

In re: PURDUE PHARMA L.P., et al.,
Debtors

Case No.: 19-23649 (RDD)
Reporting Period October 1, 2020 to October 31, 2020

SCHEDULE OF POST PETITION TAXES

Office of the U. S. Trustee

Re: Monthly Operating Report Attestation Regarding Post Petition Taxes

The Debtor, PURDUE PHARMA L.P. and its affiliate Debtors hereby submit this attestation regarding post petition taxes.

All post petition taxes, which are not subject to dispute or reconciliation, are current. There are no material disputes or reconciliations.

J. R. house
Signature

In re: PURDUE PHARMA L.P., et al.,
Debtors

Case No.: 19-23649 (RDD)
Reporting Period October 1, 2020 to October 31, 2020

SCHEDULE OF PAYMENTS TO INSIDERS (\$)

NAME	AMOUNT PAID DURING THE REPORTING PERIOD	CUMULATIVE ¹
Compensation		
Chomiak, Caroline	\$ -	\$ 261,662
Kesselman, Marc L ²	1,745,256	5,764,156
Landau, Craig J	340,723	4,067,140
Lowne, Jonathan R	114,388	1,995,148
Lundie, David R	100,261	1,652,448
Mancinelli II, Vincent F	61,562	955,633
Mazzi, Christian	-	439,030
Medeiros, Paul	60,013	1,280,482
Shamblen, Randy	60,255	939,579
Strassburger, Philip C	-	1,614,331
Total Compensation	2,482,457	18,969,609
Director Fees		
Boer, F Peter	-	875,000
Buckfire, Kenneth A	-	875,000
Cola, Michael	-	875,000
Collins, Michael J	-	25,000
Dubel, John	-	875,000
Miller, Robert S	208,333	2,500,000
Muhlhauser, Eckhard	-	25,000
Pickett, Cecil	-	875,000
Total Director Fees	208,333	6,925,000
T&E Reimbursements		
Boer, F Peter	-	10,907
Buckfire, Kenneth A	-	1,565
Chomiak, Caroline	-	30,408
Cola, Michael	-	1,388
Debone, Louis	-	1,245
Dubel, John	-	4,714
Kesselman, Marc L	1,743	51,287
Landau, Craig J	3,369	76,740
Lowne, Jonathan R	70	1,904
Lundie, David R	-	28,913
Mancinelli II, Vincent F	589	41,946
Mazzi, Christian	-	3,734
Medeiros, Paul	78	38,687
Miller, Robert S	-	9,765
Pickett, Cecil	-	1,298
Shamblen, Randy	73	11,660
Strassburger, Philip C	-	16,150
Total T&E Reimbursements	5,922	332,310
Housing Payments		
Kesselman, Marc L	4,673	69,868
Total Housing Payments	4,673	69,868

In re: PURDUE PHARMA L.P., et al.,
Debtors

Case No.: 19-23649 (RDD)
Reporting Period October 1, 2020 to October 31, 2020

SCHEDULE OF PAYMENTS TO INSIDERS (\$)

NAME	AMOUNT PAID DURING THE REPORTING PERIOD	CUMULATIVE ¹
<i>Indemnification Payments</i>		
Baker, Stuart D ³	539	1,035,450
Butcher, James A	-	527
Friedman, Michael	14,952	205,186
Landau, Craig J	392,142	2,135,578
Lundie, David R	3,799	25,677
Motahari, Saeed	-	24,680
Roncalli, Anthony	57,284	450,534
Stewart, John	7,154	184,194
Timney, Mark	35,116	1,115,817
Purdue Pharma Inc Independent Directors ⁴	314,522	1,446,555
Total Indemnification Payments	825,507	6,624,198
 <i>Payments to Independent Associated Companies</i>		
Mundibiopharma Ltd	-	55,332
Mundipharma DC BV	18,124	281,627
Mundipharma International Ltd	-	11,053
Mundipharma International Technical Operations Ltd	-	17,386
Mundipharma IT Services Ltd	-	278,603
Mundipharma Laboratories GmbH	-	916,775
Mundipharma Research Ltd	-	113,807
Mundipharma Singapore Holdings Pte Ltd	-	60,675
One Stamford Realty L.P.	747,823	13,413,425
Pharmaceutical Research Associates Inc.	592,262	1,549,645
Purdue Pharma Canada	542,157	5,219,276
Terramar Foundation	1,000	1,000
TXP Services Inc. ⁵	65,084	6,685,029
Total Payments to Independent Associated Companies	1,966,451	28,603,632
Total Payments to Insiders	\$ 5,493,344	\$ 61,524,617

Footnotes

- 1) Represents payments made since the Commencement Date.
- 2) Automobile allowance for Marc L. Kesselman is partially received in cash and partially through personal usage of a company-owned vehicle.
- 3) Indemnification payments made in June 2020 on behalf of Stuart D. Baker were inadvertently in amounts exceeding the 50% reimbursement rate approved by the Special Committee of Purdue Pharma Inc.'s Board of Directors, totaling \$12,390. Overpayments are in the process of being reversed through future invoice credits, repayment from respective law firms, and/or reimbursement from Stuart D. Baker. Currently, \$8,387.80 of this total remains outstanding.
- 4) These indemnification payments relate to litigation in which the following current and former Independent Directors of Purdue Pharma Inc. are all listed as defendants: Boer, F Peter; Costa, Paolo; Lewent, Judy; Pickett, Cecil; and Snyderman, Ralph.
- 5) Payments to TXP include a monthly charge of approximately \$58,333 for Anthony Roncalli's service as a Director for Purdue Pharma Inc.

In re: PURDUE PHARMA L.P., et al.,
Debtors

Case No.: 19-23649 (RDD)
Reporting Period October 1, 2020 to October 31, 2020

SCHEDULE OF RETAINED RESTRUCTURING PROFESSIONAL FEES (\$)

NAME	AMOUNT PAID DURING THE REPORTING PERIOD	CUMULATIVE ^{1,2}
<i>Estate Professionals</i>		
Davis Polk & Wardwell LLP	\$ 5,453,513	\$ 53,658,133
AlixPartners, LLP	827,783	13,743,247
PJT Partners LP	-	2,079,940
Ernst & Young	200,000	1,051,000
Cornerstone Research	471,819	618,980
Prime Clerk LLC	-	47,540,611
Total Estate Professionals	6,953,115	118,691,910
<i>Creditor Committee Professionals</i>		
Akin Gump Strauss Hauer & Feld LLP	4,051,526	35,302,410
Bayard, P.A.	-	949,214
Cole Schotz P.C.	1,611,624	5,724,372
Jefferies LLC	191,536	2,301,361
KPMG	-	2,887,883
Province, Inc.	1,117,938	11,506,539
Kurtzman Carson Consultants LLC	-	334,277
Bedell Cristin	18,074	53,275
Total Creditor Committee Professionals	6,990,697	59,059,330
<i>Ad Hoc Committee Professionals</i>		
Kramer Levin Naftalis & Frankel LLP	335,119	4,648,865
Brown Rudnick LLP	185,432	2,164,496
Gilbert LLP	-	2,317,727
Otterbourg PC	116,120	1,086,718
FTI Consulting, Inc	299,899	5,371,748
Houlihan Lokey	828,536	828,536
Compass Lexcon	-	-
Coulter & Justice	-	-
Total Ad Hoc Committee Professionals	1,765,107	16,418,089
<i>Special Counsel to the Debtors</i>		
Arnold Porter & Kaye Scholer	160,045	1,490,831
Dechert LLP	1,803,894	1,803,894
Jones Day	-	1,966,306
King & Spalding LLP	3,472,656	14,595,765
Skadden, Arps, Slate, Meagher & Flom LLP	-	10,154,354
Wilmer Cutler Pickering Hale and Dorr LLP	22,507	749,415
Total Special Counsel Professionals	5,459,101	30,760,565
<i>The Law Offices of Kenneth Feinberg (Mediator)</i>		
Phillips ADR (Mediator)	500,000	4,002,648
Bielli & Klauder, LLC (Fee Examiner)	500,000	4,004,089
Tom Vilsack (Court appointed monitor)	44,000	171,375
Ernst & Young (Canada), Court Appointed Information Officer	9,425	157,900
Total Retained Restructuring Professional Fees	\$ 22,221,446	\$ 233,464,451

Footnotes

1) Represents payments made since the Commencement Date

2) Prior periods may have been corrected to include payments erroneously omitted in earlier reports

In re: PURDUE PHARMA L.P., et al.,
Debtors

Case No.: 19-23649 (RDD)
Reporting Period October 1, 2020 to October 31, 2020

DEBTOR QUESTIONNAIRE

Must be completed each month. If the answer to any of the questions is "Yes", provide a detailed explanation of each item. Attach additional sheets if necessary.	Yes	No	Comments
Have any assets been sold or transferred outside the normal course of business this reporting period?		X	
Have any funds been disbursed from any account other than a debtor in possession account this reporting period?		X	
Is the Debtor delinquent in the timely filing of any post-petition tax returns?		X	
Are workers compensation, general liability or other necessary insurance coverages expired or cancelled, or has the debtor received notice of expiration or cancellation of such policies?		X	
Is the Debtor delinquent in paying any insurance premium payment?		X	
Have any payments been made on pre-petition liabilities this reporting period?	X		Payments made pursuant to certain First Day Orders were made during the period.
Are any post petition receivables (accounts, notes or loans) due from related parties?	X		Purdue Pharma, LP receives royalties from affiliated entities for foreign sales of certain products.
Are any post petition payroll taxes past due?		X	
Are any post petition State or Federal income taxes past due?		X	
Are any post petition real estate taxes past due?		X	
Are any other post petition taxes past due?		X	
Have any pre-petition taxes been paid during this reporting period?		X	
Are any amounts owed to post petition creditors delinquent?		X	
Are any wage payments past due?		X	
Have any post petition loans been received by the Debtor from any party?		X	
Is the Debtor delinquent in paying any U.S. Trustee fees?		X	
Is the Debtor delinquent with any court ordered payments to attorneys or other professionals?		X	
Have the owners or shareholders received any compensation outside of the normal course of business?		X	